Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives

Jung, 2020, Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 52, 1603, 10.1111/apt.16066 Younossi, 2019, Non-alcoholic fatty liver disease - a global public health perspective, J Hepatol, 70, 531, 10.1016/j.jhep.2018.10.033 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 Povsic, 2019, A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH), Adv Ther, 36, 1574, 10.1007/s12325-019-00960-3 Allen, 2018, Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study, Hepatology, 67, 1726, 10.1002/hep.29546 Zhang, 2016, Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial, JAMA Intern Med, 176, 1074, 10.1001/jamainternmed.2016.3202 Goldberg, 2017, Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation, Gastroenterology, 152 Zhou, 2019, Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis, Hepatology, 70, 1119, 10.1002/hep.30702 Ratziu, 2015, Current efforts and trends in the treatment of NASH, J Hepatol, 62, S65, 10.1016/j.jhep.2015.02.041 Romero, 2020, The race to bash NASH: emerging targets and drug development in a complex liver disease, J Med Chem, 63, 5031, 10.1021/acs.jmedchem.9b01701 Khan, 2019, Modulation of insulin resistance in nonalcoholic fatty liver disease, Hepatology, 70, 711, 10.1002/hep.30429 Ioannou, 2016, The role of cholesterol in the pathogenesis of NASH, Trends Endocrinol Metab, 27, 84, 10.1016/j.tem.2015.11.008 Schuppan, 2018, Determinants of fibrosis progression and regression in NASH, J Hepatol, 68, 238, 10.1016/j.jhep.2017.11.012 Cai, 2019, The role of innate immune cells in nonalcoholic steatohepatitis, Hepatology, 70, 1026, 10.1002/hep.30506 Schuster, 2018, Triggering and resolution of inflammation in NASH, Nat Rev Gastroenterol Hepatol, 15, 349, 10.1038/s41575-018-0009-6 Hirsova, 2020, Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis, Cell Death Dis, 11, 80, 10.1038/s41419-020-2283-9 Younossi, 2019, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 394, 2184, 10.1016/S0140-6736(19)33041-7 Harrison, 2018, Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis, Gastroenterology, 155, 1140, 10.1053/j.gastro.2018.07.006 Loomba, 2021, Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH, Hepatology, 73, 625, 10.1002/hep.31622 Cicero, 2018, Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence, Nutrients, 10, 1153, 10.3390/nu10091153 Borrelli, 2018, Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches, Redox Biol, 15, 467, 10.1016/j.redox.2018.01.009 Bessone, 2019, Molecular pathways of nonalcoholic fatty liver disease development and progression, Cell Mol Life Sci, 76, 99, 10.1007/s00018-018-2947-0 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Schmitz, 2020, Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems, BMC Gastroenterol, 20, 254, 10.1186/s12876-020-01400-1 Vilar-Gomez, 2018, Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers, J Hepatol, 68, 305, 10.1016/j.jhep.2017.11.013 Abdelmalek, 2021, Nonalcoholic fatty liver disease: another leap forward, Nat Rev Gastroenterol Hepatol, 18, 85, 10.1038/s41575-020-00406-0 Horn, 2022, Role of cholesterol-associated steatohepatitis in the development of NASH, Hepatol Commun, 6, 12, 10.1002/hep4.1801 Scorletti, 2022, A new perspective on NAFLD: focusing on lipid droplets, J Hepatol, 76, 934, 10.1016/j.jhep.2021.11.009 Liebold, 2021, Apoptotic cell signals and heterogeneity in macrophage function: fine-tuning for a healthy liver, Semin Cell Dev Biol, 119, 72, 10.1016/j.semcdb.2021.06.012 Cariou, 2021, Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review, Diabetes Obes Metab, 23, 1069, 10.1111/dom.14322 Galicia-Garcia, 2020, Pathophysiology of type 2 diabetes mellitus, Int J Mol Sci, 21, 6275, 10.3390/ijms21176275 Finck, 2018, Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis, Diabetes, 67, 2485, 10.2337/dbi18-0024 Loomba, 2009, Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 29, 172, 10.1111/j.1365-2036.2008.03869.x Harrison, 2020, Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study, J Hepatol, 72, 613, 10.1016/j.jhep.2019.10.023 Kuhre, 2016, The regulation of function, growth and survival of GLP-1-producing L-cells, Clin Sci (Lond), 130, 79, 10.1042/CS20150154 Sumida, 2020, Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis, Int J Mol Sci, 21, 1907, 10.3390/ijms21061907 Armstrong, 2016, Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis, J Hepatol, 64, 399, 10.1016/j.jhep.2015.08.038 Cegla, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study, Ann Clin Biochem, 53, 518, 10.1177/0004563216648250 O'Neil, 2018, Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial, Lancet, 392, 637, 10.1016/S0140-6736(18)31773-2 Newsome, 2021, A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, N Engl J Med, 384, 1113, 10.1056/NEJMoa2028395 Harrison, 2020, Semaglutide for the treatment of non-alcoholic steatohepatitis: trial design and comparison of non-invasive biomarkers, Contemp Clin Trials, 97, 10.1016/j.cct.2020.106174 Chao, 2019, Homeostasis of glucose and lipid in non-alcoholic fatty liver disease, Int J Mol Sci, 20, 298, 10.3390/ijms20020298 Mirarchi, 2022, SGLT2 inhibitors as the Most promising influencers on the outcome of non-alcoholic fatty liver disease, Int J Mol Sci, 23, 3668, 10.3390/ijms23073668 Gutierrez, 2021, Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction, Mol Metab, 48, 10.1016/j.molmet.2021.101196 Futatsugi, 2020, Discovery of PF-06835919: a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose, J Med Chem, 63, 13546, 10.1021/acs.jmedchem.0c00944 Ishimoto, 2012, Opposing effects of fructokinase C and a isoforms on fructose-induced metabolic syndrome in mice, Proc Natl Acad Sci U S A, 109, 4320, 10.1073/pnas.1119908109 Attia, 2021, Evolving role for pharmacotherapy in NAFLD/NASH, Clin Transl Sci, 14, 11, 10.1111/cts.12839 Ross, 2020, Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems, Cell Mol Gastroenterol Hepatol, 10, 829, 10.1016/j.jcmgh.2020.06.001 Cho, 2010, Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK, Biochem Biophys Res Commun, 391, 187, 10.1016/j.bbrc.2009.11.029 Lawitz, 2018, Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic De novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 16 Loomba, 2018, GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease, Gastroenterology, 155 Alkhouri, 2020, GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH), Expert Opin Investig Drugs, 29, 135, 10.1080/13543784.2020.1668374 Calle, 2021, ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials, Nat Med, 27, 1836, 10.1038/s41591-021-01489-1 Jones, 2015, Molecular pathways: fatty acid synthase, Clin Cancer Res, 21, 5434, 10.1158/1078-0432.CCR-15-0126 Loomba, 2021, TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial, Gastroenterology, 161, 1475, 10.1053/j.gastro.2021.07.025 Al, 2017, Insights into stearoyl-CoA Desaturase-1 regulation of systemic metabolism, Trends Endocrinol Metab, 28, 831, 10.1016/j.tem.2017.10.003 Yamada, 2015, Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis, Liver Int, 35, 582, 10.1111/liv.12685 Ratziu, 2021, Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial, Nat Med, 27, 1825, 10.1038/s41591-021-01495-3 Alves-Bezerra, 2017, Triglyceride metabolism in the liver, Compr Physiol, 8, 1 Devasthale, 2018, Monoacylglycerol acyltransferase 2 (MGAT2) inhibitors for the treatment of metabolic diseases and nonalcoholic steatohepatitis (NASH), J Med Chem, 61, 9879, 10.1021/acs.jmedchem.8b00864 Amin, 2019, Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis, Sci Transl Med, 11, 10.1126/scitranslmed.aav9701 Pawlak, 2015, Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease, J Hepatol, 62, 720, 10.1016/j.jhep.2014.10.039 Huang, 2022, Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL), Int J Mol Sci, 23 Harrison, 2021, Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial, Nat Med, 27, 1262, 10.1038/s41591-021-01425-3 Verzijl, 2020, Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis, Expert Opin Investig Drugs, 29, 125, 10.1080/13543784.2020.1708898 Sanyal, 2019, Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial, Lancet, 392, 2705, 10.1016/S0140-6736(18)31785-9 Boeckmans, 2019, Anti-NASH drug development hitches a lift on PPAR agonism, Cells, 9, 37, 10.3390/cells9010037 Nakajima, 2021, Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 54, 1263, 10.1111/apt.16596 Jones, 2017, Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study, Lancet Gastroenterol Hepatol, 2, 716, 10.1016/S2468-1253(17)30246-7 Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326 Bril, 2018, Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes, Clin Gastroenterol Hepatol, 16 Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774 Ratziu, 2010, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002/hep.23270 Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150 Francque, 2021, A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH, N Engl J Med, 385, 1547, 10.1056/NEJMoa2036205 Schumacher, 2021, Posttranslational regulation of HMG CoA reductase, the rate-limiting enzyme in synthesis of cholesterol, Annu Rev Biochem, 90, 659, 10.1146/annurev-biochem-081820-101010 Mullur, 2014, Thyroid hormone regulation of metabolism, Physiol Rev, 94, 355, 10.1152/physrev.00030.2013 Harrison, 2019, Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 394, 2012, 10.1016/S0140-6736(19)32517-6 Hu, 2021, Structural insights into the mechanism of human NPC1L1-mediated cholesterol uptake, Sci Adv, 7, 10.1126/sciadv.abg3188 Zhang, 2022, Niemann-pick C1-like 1 inhibitors for reducing cholesterol absorption, Eur J Med Chem, 230, 10.1016/j.ejmech.2022.114111 Lin, 2016, Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial, Therap Adv Gastroenterol, 9, 152, 10.1177/1756283X15621232 Chow, 2017, The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Mol Aspects Med, 56, 34, 10.1016/j.mam.2017.04.004 Chambers, 2019, Polyphenol effects on cholesterol metabolism via bile acid biosynthesis, CYP7A1: a review, Nutrients, 11, 2588, 10.3390/nu11112588 Winston, 2020, Diversification of host bile acids by members of the gut microbiota, Gut Microbes, 11, 158, 10.1080/19490976.2019.1674124 Arab, 2017, Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives, Hepatology, 65, 350, 10.1002/hep.28709 Sciarrillo, 2021, Fibroblast growth factor 19: potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease, Liver Int, 41, 894, 10.1111/liv.14802 Fiorucci, 2020, Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH), Expert Opin Investig Drugs, 29, 623, 10.1080/13543784.2020.1763302 Huang, 2021, A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage, Metabolism, 120, 10.1016/j.metabol.2021.154797 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Ratziu, 2022, EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study, J Hepatol, 76, 506, 10.1016/j.jhep.2021.10.018 Patel, 2020, Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial, Hepatology, 72, 58, 10.1002/hep.31205 Talukdar, 2021, FGF19 and FGF21: in NASH we trust, Mol Metab, 46, 10.1016/j.molmet.2020.101152 Harrison, 2018, NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 391, 1174, 10.1016/S0140-6736(18)30474-4 Harrison, 2022, Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Gastroenterol Hepatol, 7, 603, 10.1016/S2468-1253(22)00017-6 Fiorucci, 2015, Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders, Trends Mol Med, 21, 702, 10.1016/j.molmed.2015.09.001 Al-Dury, 2018, Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH, Front Pharmacol, 9, 931, 10.3389/fphar.2018.00931 Newsome, 2020, Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study, J Hepatol, 73, 231, 10.1016/j.jhep.2020.03.024 Hirsova, 2015, Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis, Cell Mol Gastroenterol Hepatol, 1, 17, 10.1016/j.jcmgh.2014.11.005 Tamimi, 2011, An apoptosis panel for nonalcoholic steatohepatitis diagnosis, J Hepatol, 54, 1224, 10.1016/j.jhep.2010.08.023 Brenner, 2013, Decoding cell death signals in liver inflammation, J Hepatol, 59, 583, 10.1016/j.jhep.2013.03.033 Loomba, 2018, The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial, Hepatology, 67, 549, 10.1002/hep.29514 Harrison, 2020, Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials, J Hepatol, 73, 26, 10.1016/j.jhep.2020.02.027 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-National Cohort Study, Gastroenterology, 155 Tacke, 2021, Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention, Ann Transl Med, 9, 729, 10.21037/atm-20-4354 Ratziu, 2020, Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study, Hepatology, 72, 892, 10.1002/hep.31108 Friedman, 2018, A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis, Hepatology, 67, 1754, 10.1002/hep.29477 Lefebvre, 2016, Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment, Clin Transl Sci, 9, 139, 10.1111/cts.12397 Anstee, 2020, Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design, Contemp Clin Trials, 89, 10.1016/j.cct.2019.105922 Ikenaga, 2017, Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal, Gut, 66, 1697, 10.1136/gutjnl-2016-312473 Harrison, 2018, Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial, PLoS One, 13, 10.1371/journal.pone.0203054 Chalasani, 2020, Effects of belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension, Gastroenterology, 158 Pizarro, 2015, Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis, Liver Int, 35, 2129, 10.1111/liv.12794 Takai, 2020, Chymase as a possible therapeutic target for amelioration of non-alcoholic steatohepatitis, Int J Mol Sci, 21, 7543, 10.3390/ijms21207543 Okanoue, 2021, Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: a randomized controlled study, Hepatol Res, 51, 943, 10.1111/hepr.13695 Moreno, 2010, Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats, Hepatology, 51, 942 McPherson, 2017, A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis, PLoS One., 12, 10.1371/journal.pone.0175717 Nati, 2016, The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH), Rev Endocr Metab Disord, 17, 29, 10.1007/s11154-016-9339-2 Luci, 2020, Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies, Front Endocrinol (Lausanne)., 11, 10.3389/fendo.2020.597648 Kolodziejczyk, 2019, The role of the microbiome in NAFLD and NASH, EMBO Mol Med, 11, 10.15252/emmm.201809302 Mouries, 2019, Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development, J Hepatol, 71, 1216, 10.1016/j.jhep.2019.08.005 Park, 2021, Role of microbiota-derived metabolites in alcoholic and non-alcoholic fatty liver diseases, Int J Mol Sci, 23, 426, 10.3390/ijms23010426 Buzzetti, 2016, The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD), Metabolism, 65, 1038, 10.1016/j.metabol.2015.12.012 Ibrahim, 2018, Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation, Gut, 67, 963, 10.1136/gutjnl-2017-315691 Bomhof, 2019, Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial, Eur J Nutr, 58, 1735, 10.1007/s00394-018-1721-2 Sumida, 2018, Current and future pharmacological therapies for NAFLD/NASH, J Gastroenterol, 53, 362, 10.1007/s00535-017-1415-1 Torok, 2015, Vascular adhesion protein 1 in nonalcoholic steatohepatitis: a novel biomarker?, Hepatology, 62, 1313, 10.1002/hep.27942 Li, 2020, C-mpl and TPO expression in the human central nervous system neurons inhibits neuronal apoptosis, Aging (Albany NY)., 12, 7397, 10.18632/aging.103086 Lee, 2014, The emerging landscape of RORgammat biology, Immunity, 40, 451, 10.1016/j.immuni.2014.04.005 Violi, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 363, 1185, 10.1056/NEJMc1006581 Bril, 2019, Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial, Diabetes Care, 42, 1481, 10.2337/dc19-0167 Argo, 2015, Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial, J Hepatol, 62, 190, 10.1016/j.jhep.2014.08.036 Younossi, 2021, Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life, Clin Gastroenterol Hepatol, 20, 1354, 10.1016/j.cgh.2021.07.039 Younossi, 2021, Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: regenerate 18-month interim analysis, Clin Gastroenterol Hepatol, 19, 00751 Wang, 2021, Safety, pharmacokinetics, pharmacodynamics, and formulation of liver-distributed farnesoid X-receptor agonist TERN-101 in healthy volunteers, Clin Pharmacol Drug Dev, 10, 1198, 10.1002/cpdd.960 Harrison, 2021, Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis, Gastroenterology, 160 Siebers, 2018, Absorption, distribution, metabolism, and excretion of [(14)C]-volixibat in healthy men: phase 1 open-label study, Eur J Drug Metab Pharmacokinet, 43, 91, 10.1007/s13318-017-0429-7 Harrison, 2020, A randomized, placebo-controlled trial of emricasan in patients with NASH and F1–F3 fibrosis, J Hepatol, 72, 816, 10.1016/j.jhep.2019.11.024 Garcia-Tsao, 2020, Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension, J Hepatol, 72, 885, 10.1016/j.jhep.2019.12.010 Sebastiani, 2020, Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients, AIDS, 34, 237, 10.1097/QAD.0000000000002412 Kitson, 2016, High-dose vitamin D supplementation and liver histology in NASH, Gut, 65, 717, 10.1136/gutjnl-2015-310417 Ebrahimpour-Koujan, 2019, Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial, Trials, 20, 153, 10.1186/s13063-019-3241-7 Zein, 2011, Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial, Hepatology, 54, 1610, 10.1002/hep.24544 Van Wagner, 2011, Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial, Ann Hepatol, 10, 277, 10.1016/S1665-2681(19)31539-X Afdhal, 2012, Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia, N Engl J Med, 367, 716, 10.1056/NEJMoa1110709 Dufour, 2020, Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges, Gut, 69, 1877, 10.1136/gutjnl-2019-319104 Alkhouri, 2022, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial, J Hepatol, 10.1016/j.jhep.2022.04.003 Pockros, 2019, CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients, Liver Int, 39, 2082, 10.1111/liv.14209 Culafic, 2020, Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis, J Med Biochem., 39, 290 Oliveira, 2019, N-acetylcysteine and/or ursodeoxycholic acid associated with metformin in non-alcoholic steatohepatitis: an open-label multicenter randomized controlled trial, Arq Gastroenterol, 56, 184, 10.1590/s0004-2803.201900000-36 Zohrer, 2017, Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial, Appl Physiol Nutr Metab, 42, 948, 10.1139/apnm-2016-0689 Lawitz, 2022, Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat, Clin Gastroenterol Hepatol Dehnad, 2020, AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes, J Clin Invest, 130, 4320 Liu, 2021, Squalene epoxidase induces nonalcoholic steatohepatitis via binding to carbonic anhydrase III and is a therapeutic target, Gastroenterology, 160 Fondevila, 2021, The L-alpha-Lysophosphatidylinositol/G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis, Hepatology, 73, 606, 10.1002/hep.31290